Success Stories: Assistant Researcher in Proteomics from India Obtains EB1-A Approval in Just 38 Days, Thanks to Premium Processing and Our Team’s Effort

 

Client’s Testimonial:

“Thank you for making my I-140 a successful case. Your timely responses and thorough review of my application are greatly appreciated. It was a pleasure working with you.”


On March 21st, 2022, we received another EB-1A (Alien of Extraordinary Ability) approval for an Assistant Researcher in the Field of Proteomics (Approval Notice).


General Field: Proteomics

Position at the Time of Case Filing: Assistant Researcher

Country of Origin: India

State of Residence at the Time of Filing: California

Approval Notice Date: March 21st, 2022

Processing Time: 1 month, 10 days (Premium Processing Requested)


Case Summary:

“[Client’s] work on mass-spectrometry-based mechanistic studies of disease has directly addressed these needs in healthcare and biomedicine, providing individuals diagnosed with DM with more effective therapeutic interventions and care options. Bearing in mind that no cure has been developed for DM, [client’s] ongoing research is critical in nature.”

“[The client’s] research is beneficial for understanding diabetes, as it helps to classify site-specific protein glycation. This expands our understanding of the non-enzymatic process that causes numerous diabetes complications. The usefulness of [the client’s] innovative findings to her peers serve to advance the proteomics field and, subsequently, treatment options for diabetes patients.”

Two statements were issued in favor of an Indian assistant researcher working in proteomics. As it happened, she had come to the North America Immigration Law Group seeking help with her EB1-A (Alien of Extraordinary Ability) visa processing. Given her vast experience in the field and our team’s expertise, we got her the approval in just 38 days of filing. However, this needed careful deliberation on our part. Our team ensured that her petition packet was explicitly tailored to her strengths. This meant looking in depth at her CVs, transcripts, certificates, letters of recommendation, etc.

We were able to gather the following information from these academic and professional documents:

  • Details of her proposed research work: She wants to continue her work on the protein-protein interactions involved in SARS-CoV-2 infection and her work on performing a structural and biophysical characterization of tau protein, a key protein in the development and progression of Alzheimer’s disease.
  • Peer-review experience: The field has recognized her authority by inviting her to review and evaluate the work of her peers no fewer than 6 times.
  • Publication count: She has actively engaged her peers in the field of proteomics by authoring and co-authoring 17 peer-reviewed articles and 1 preprint that have been published in international journals.
  • Citation count: Her overall work related to the improvement of mass spectrometry-based approaches to structural proteomics has been cited 607 times in at least 49 countries by peers using her prior findings to make additional discoveries. She is one of the top 1% most highly cited authors publishing on topics in Chemistry over the past 10 years according to Microsoft Academic.
  • Letters of recommendation: All of this evidence is fully supported and corroborated by 4 letters of recommendation from internationally recognized experts in the field who have used her work in their own research endeavors and attest to its influence and major significance.
The totality of these pieces of evidence was enough to show that she is one of that small percentage who has risen to the very top of her field and has sustained both national and international acclaim, thus, fulfilling the most important criterion of the EB1-A category visa. This is why her approval came through without an RFE. We are glad to have had the opportunity to represent her in this case and we wish her the best of luck.